Weight Loss on Ozempic: Clinical Evidence & Personalization

Last reviewed: June 1, 2026

Last updated: June 1, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Yes, GLP-1 receptor agonists like semaglutide have demonstrated meaningful weight loss in clinical trials—with average reductions of 15-22% body weight over 68 weeks in the STEP trials. However, individual outcomes vary significantly, and understanding what may influence your personal response is essential for informed decision-making with your provider.

Weight loss success depends on multiple factors: medication choice, dosing adherence, lifestyle integration, and individual metabolic biology. PlexusDx takes a precision-wellness approach, helping you understand your genetic predispositions in peptide and metabolic pathways so you can have a more informed conversation with your healthcare provider about which treatment may be right for you.

How GLP-1 Medications Work for Weight Loss

GLP-1 receptor agonists mimic glucagon-like peptide-1, a hormone that regulates appetite and blood sugar. These medications signal satiety in the brain, slow gastric emptying, and reduce hunger hormones. The result: decreased caloric intake and sustained weight reduction without requiring extreme dietary restriction.

Semaglutide (the active compound in branded Ozempic and Wegovy) works across multiple systems simultaneously. Clinical data shows effectiveness in both weight loss and metabolic improvement, making it relevant for patients with obesity and metabolic syndrome. However, response magnitude varies—some patients lose 10% body weight, others 25% or more.

Clinical Evidence: What the Data Actually Shows

Multiple randomized controlled trials have established GLP-1 efficacy. The STEP program enrolled over 4,500 patients with obesity; those receiving semaglutide achieved mean weight loss of 15.3 kg compared to 2.6 kg with placebo over 68 weeks. Cardiovascular outcomes also improved in long-term follow-up studies.

Real-world data from prescription tracking shows sustained weight loss over 12-24 months when patients maintain medication adherence and lifestyle changes. However, weight regain occurs in most patients after discontinuation, indicating GLP-1 medications work as ongoing treatments rather than one-time interventions.

Metric	Semaglutide Data (STEP Trials)	Clinical Context
Average Weight Loss	15.3 kg (33.7 lbs) over 68 weeks	Significantly greater than placebo
Percentage Body Weight Reduction	15-22% mean reduction	Varies by individual baseline and adherence
Cardiovascular Benefits	Reduced major cardiovascular events	Important for patients with obesity and comorbidities
Discontinuation Weight Regain	70-80% regain within 1-2 years	Suggests ongoing treatment needed for maintenance

Why Individual Response Varies: The Genetic and Metabolic Component

Not all patients respond identically to GLP-1 medications. Genetic variations in the GLP1R gene (such as rs6923761), MC4R gene (rs17782313), and FTO gene (rs9939609) influence how your body processes appetite signals and metabolic regulation. These variations may predispose you toward different treatment responses.

Beyond genetics, insulin resistance, baseline body composition, age, and gastrointestinal tolerance affect outcomes. A patient with insulin resistance may see additional metabolic benefits; someone with rapid gastric motility may tolerate higher doses differently. These individual factors underscore why a one-size-fits-all approach rarely works in weight management.

Safety Considerations and Who Should Consider This Treatment

GLP-1 medications are generally well-tolerated but not appropriate for everyone. Common side effects include nausea, vomiting, and constipation—typically mild and transient. Contraindications include personal or family history of medullary thyroid cancer and multiple endocrine neoplasia type 2. Pregnancy and nursing also require discontinuation.

Ideal candidates typically have a BMI over 30 or BMI over 27 with weight-related comorbidities (hypertension, type 2 diabetes, sleep apnea). Your healthcare provider must evaluate medical history, current medications, kidney function, and gastrointestinal health before initiating treatment. Close monitoring during dose escalation is essential for safety and tolerability.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test examines variants in GLP1R, MC4R, FTO, and GIPR genes to reveal predispositions in your peptide and metabolic pathways. This information may help provide context for how your body may respond to GLP-1 medications, but should be interpreted alongside clinical assessment and provider guidance—genetic predisposition is not a prediction of exact medication response.

The genetic test reveals whether you carry variants associated with enhanced GLP-1 receptor sensitivity, metabolic inflexibility, or appetite regulation patterns. For example, certain GLP1R variants may correlate with stronger satiety signaling in some individuals. Understanding these predispositions can support a more informed conversation about which medication approach or dosing strategy your provider might recommend.

PlexusDx compounded semaglutide and tirzepatide medications offer cost-effective access starting at $149/month and $249/month respectively, with pricing that remains flat across commitment tiers—your dose may need to go up, but your price won't. Combined with genetic insights, this approach enables precision-guided treatment tailored to your unique physiology.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Oral starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.